 |
JOURNAL TOOLS |
| Publishing options |
| eTOC |
| To subscribe |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Publication history |
| Reprints |
| Permissions |
| Cite this article as |
| Share |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
EDITORIAL Free access
Minerva Anestesiologica 2019 May;85(5):465-7
DOI: 10.23736/S0375-9393.19.13711-X
Copyright © 2019 EDIZIONI MINERVA MEDICA
language: English
Why do we give “orphan” approval to biologic therapies but not to extracorporeal blood purification therapies for hyperinflammatory syndromes?
Christopher M. HORVAT, Joseph A. CARCILLO ✉
Division of Pediatric Critical Care Medicine, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA